tradingview.com
Cure8 news brief
Why This Matters
Shattuck’s update shows active clinical development for SL-325 in Crohn’s disease and for SL-846, which could matter to patients watching new treatment research and to clinicians tracking upcoming trial readouts.
Who Should Pay Attention
Patients with Crohn’s disease, clinicians and researchers interested in emerging IBD therapies, and investors tracking biotech clinical programs.
Study Snapshot
Story typeBusiness news
Evidence typePhase 2 clinical trial
Source depthFull source text
What To Know
Shattuck Labs reported financial results and described clinical plans for two investigational drugs: SL-325, which is in a Phase 2b Crohn’s disease trial called RECEPTIVE-CD1 with induction data expected in H1 2028, and SL-846, for which a Phase 1 start and initial data are expected in 2027.
The company also plans a Phase 2b trial of SL-325 in hidradenitis suppurativa (RECEPTIVE-HS1) with primary-treatment data expected in H1 2028. The filing emphasizes increased R&D spending tied to these programs and notes preliminary preclinical chronic toxicology data for SL-846 shared in October.
This report is a summary of the company’s SEC 10-Q filing and focuses on program timelines and financial impacts rather than clinical results. If you follow investigational IBD drugs, this item signals active development timelines but does not provide efficacy or safety results for patients to act on.
Keep In Mind
This item is an AI-powered summary of an SEC 10-Q filing and company disclosures; it reports planned trial starts and expected data timelines but does not contain trial results. Timelines and plans can change; consult trial registries or company releases for updates.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationtradingview.com
Indexed viaGoogle News
Source typeWeb article
PublishedNov 5, 2026, 1:22 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Shattuck Labs Incurs Higher Q2 Loss; To Advance SL-325 In Phase 2b For Crohn's Disease In Q3 '26
Shattuck Labs plans to advance a DR3-targeting bispecific antibody (SL-325) into a Phase 2b trial for Crohn's disease, which is relevant to people watching new investigational biologics for IBD. The report is a...
PALISADE BIO, INC. Q2 2026: Revenue $0.5M, EPS $(0.05) — 10-Q Summary
If you or a loved one follow emerging IBD treatments, this update signals a new PALI-2108 program moving into Phase 2 for ulcerative colitis and planned Phase 2 testing in Crohn’s disease, plus a company focus on...
Palisade Bio Reports Q2 2026 Results, Advances PALI-2108 Into Phase 2 Development for ...
If PALI-2108 proves safe and effective in Phase 2 trials, it could add a new oral treatment option for people with ulcerative colitis and Crohn’s disease. Early Phase 1 signals and a funded Phase 2 program mean the...